130 related articles for article (PubMed ID: 38287534)
21. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
22. Decreased interleukin-21 expression in skin and blood in advanced mycosis fungoides.
Kabasawa M; Sugaya M; Oka T; Takahashi N; Kawaguchi M; Suga H; Miyagaki T; Takahashi T; Shibata S; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol; 2016 Jul; 43(7):819-22. PubMed ID: 26825047
[TBL] [Abstract][Full Text] [Related]
23. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma.
Furudate S; Fujimura T; Kakizaki A; Hidaka T; Asano M; Aiba S
J Dermatol Sci; 2016 Sep; 83(3):182-9. PubMed ID: 27342040
[TBL] [Abstract][Full Text] [Related]
24. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
Gerami P; Rosen S; Kuzel T; Boone SL; Guitart J
Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
[TBL] [Abstract][Full Text] [Related]
25. Expression of SATB1, MTI/II and Ki-67 in Mycosis Fungoides.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Bieniek A; Dziegiel P
Anticancer Res; 2016 Jan; 36(1):189-97. PubMed ID: 26722043
[TBL] [Abstract][Full Text] [Related]
26. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.
Argyropoulos KV; Pulitzer M; Perez S; Korkolopoulou P; Angelopoulou M; Baxevanis C; Palomba ML; Siakantaris M
Clin Transl Oncol; 2020 Jul; 22(7):1059-1066. PubMed ID: 31696413
[TBL] [Abstract][Full Text] [Related]
27. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
28. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA.
Asadullah K; Döcke WD; Haeussler A; Sterry W; Volk HD
J Invest Dermatol; 1996 Dec; 107(6):833-7. PubMed ID: 8941670
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of membrane markers and morphometric characteristics of lymphoid cells in blood and lymph nodes from patients with mycosis fungoides.
van der Loo EM; Meijer CJ; Scheffer E; van Vloten WA
Cancer; 1981 Aug; 48(3):738-44. PubMed ID: 6454478
[TBL] [Abstract][Full Text] [Related]
30. Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Talpur R; Thompson A; Gangar P; Duvic M
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):297-304. PubMed ID: 24589156
[TBL] [Abstract][Full Text] [Related]
31. Results of a prospective phase II trial with oral low-dose bexarotene plus photochemotherapy (PUVA) in refractory and/or relapsed patients with mycosis fungoides.
Rupoli S; Canafoglia L; Goteri G; Leoni P; Brandozzi G; Federici I; Micucci G; Giantomassi F; Mozzicafreddo G; Alterini R; Filosa G; Ricotti G; Simonacci M; Scortechini AR; Zizzi A; Pimpinelli N
Eur J Dermatol; 2016; 26(1):13-20. PubMed ID: 26678311
[TBL] [Abstract][Full Text] [Related]
32. Updated review on prognostic factors in mycosis fungoides and new skin lymphoma trials.
Farabi B; Seminario-Vidal L; Jamgochian M; Akay BN; Atak MF; Rao BK; Karagaiah P; Grabbe S; Goldust M
J Cosmet Dermatol; 2022 Jul; 21(7):2742-2748. PubMed ID: 34687485
[TBL] [Abstract][Full Text] [Related]
33. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
[TBL] [Abstract][Full Text] [Related]
34. CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation.
Hu SC; Lin CL; Hong CH; Yu HS; Chen GS; Lee CH
J Dermatol Sci; 2014 Apr; 74(1):31-8. PubMed ID: 24411580
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
36. Single-cell RNA sequencing reveals markers of disease progression in primary cutaneous T-cell lymphoma.
Rindler K; Jonak C; Alkon N; Thaler FM; Kurz H; Shaw LE; Stingl G; Weninger W; Halbritter F; Bauer WM; Farlik M; Brunner PM
Mol Cancer; 2021 Sep; 20(1):124. PubMed ID: 34583709
[TBL] [Abstract][Full Text] [Related]
37. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
38. Treatment of mycosis fungoides with bexarotene results in remission of diffuse plane xanthomas.
Gregoriou S; Rigopoulos D; Stamou C; Nikolaou V; Kontochristopoulos G
J Cutan Med Surg; 2013; 17(1):52-4. PubMed ID: 23364151
[TBL] [Abstract][Full Text] [Related]
39. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
40. Plasma TM2-PK levels in mycosis fungoides patients.
Hapa A; Erkin G; Hasçelik G; Pektaş D; Arslan U
Arch Dermatol Res; 2011 Jan; 303(1):35-40. PubMed ID: 20927531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
